Regence Rx, Inc. and Catalyst Health Solutions, Inc., (NASDAQ: CHSI) today announced an agreement that establishes Catalyst Rx as the exclusive provider of pharmacy benefit management (PBM) services for Regence Rx. The agreement is expected to be effective May 1, 2012 and the initial term runs through December 31, 2017 with a four-year optional extension. Through this agreement, Regence Rx will carve out its operational functions, and transfer related people, technology, and internal client service assets to Catalyst for them to manage and operate. Regence Rx will continue to provide clinical and contracting support to its customers. Catalyst Rx is a full-service PBM that serves more than 18 million lives in the United States and Puerto Rico. This agreement will allow Regence Rx to leverage the scale and expertise of Catalyst Rx, one of the country’s fastest growing PBMs, and its national provider network as the two organizations partner to deliver more efficient pharmacy benefit programs and better clinical outcomes for clients and individuals throughout the Pacific Northwest and Intermountain State Regions. Regence Rx currently provides PBM services for more than 1.2 million members of Regence Health Plans and provides related services to over 7.7 million members from other Blue Cross and Blue Shield and Medicaid plans. “We are excited about the opportunity to partner with Regence Rx to deliver PBM services to their clients and members,” said Catalyst Health Solutions President and Chief Operating Officer Rick Bates. “Through this collaboration, Catalyst will work with Regence Rx to establish a pharmacy Center of Excellence in the Northwest that will help us serve an even greater number of employers, individuals and communities throughout the region.” “By joining forces, our companies will be able to fulfill our mutual goal of supporting an economically sustainable health care system,” said President of Direct Health Solutions for Cambia Health Solutions, Inc., John W. Morgan. “Additionally, as we leverage Catalyst’s national provider network and contracting capabilities, investments in product development, and expanded sales and marketing resources, Regence Rx will be in a position to improve our efficiency, deliver enhanced service to our clients and leverage new opportunities to grow our business.”
Catalyst Health Solutions (Nasdaq:CHSI) hit a new 52-week high Monday as it is currently trading at $96.59, above its previous 52-week high of $96.41 with 178,069 shares traded as of 10:55 a.m. ET. Average volume has been 862,700 shares over the past 30 days.
Catalyst Health Solutions (Nasdaq:CHSI) hit a new 52-week high Monday as it is currently trading at $92.63, above its previous 52-week high of $92.62 with 358,408 shares traded as of 1:30 p.m. ET. Average volume has been 833,500 shares over the past 30 days.